ANGPTL8 and metabolic dysfunction-associated steatotic liver disease: (43), which reported lower circulating ANGPTL8 levels in patients with biopsy-proven NAFLD compared to healthy controls, further showed that the lowest levels were in those with significant fibrosis compared to those with mild fibrosis.